[Effect of bis-(isobutyryloxy-2-ethyl)-1-N-(amino-4-methyl-2-pyrimidyl-5) methyl formamido-2-propene-1-yl disulfide (Sulbutiamin) in neurasthenic and neuroastheniform syndromes].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D001247:Asthenia / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009440:Neurasthenia / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use; D013831:Thiamine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000928:Antidepressive Agents; D011619:Psychotropic Drugs; C031331:sulbutiamine; D013831:Thiamine
Effeto del disolfuro di bis-(isobutirrilossi-2-etile)-1-N-(amino-4-metil-2-pirimidil-5) metil formamido-2-propene-1-ile (Sulbutiamina) nelle sindromi neurasteniche e neuroasteniformi.